J&J raises FY26 outlook following positive Q2

Johnson & Johnson (JNJ) announced an upward revision to its fiscal year 2026 outlook following a strong second quarter. The company reported better-than-expected earnings and revenue, reflecting solid performance across its pharmaceutical, medical devices, and consumer health segments. The updated guidance suggests the company is optimistic about its growth trajectory for the remainder of the year. The specific figures for the revised outlook were not disclosed in the source. This positive update may influence investor sentiment and could support the company's stock performance in the near term. The announcement underscores J&J's resilience amid market fluctuations and ongoing industry challenges. Market participants will likely monitor subsequent quarterly results to assess whether the outlook revision translates into sustained growth.